<?xml version="1.0" encoding="UTF-8" standalone="no"?>
<ibecs-document>
<record>
<header>
<identifier>ibc-138572</identifier>
<setSpec>0025-7753</setSpec>
</header>
<metadata xmlns="http://example.org/myapp/" xmlns:dc="http://purl.org/dc/elements/1.1/" xmlns:dcterms="http://purl.org/dc/terms/" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xsi:schemaLocation="http://example.org/myapp/schema.xsd">
<dc:title xml:lang="en">Alzheimer's disease: New therapeutic strategies</dc:title>
<dc:description xml:lang="en">The rapid increase in prevalence rates of Alzheimer's disease means that treatments to prevent, stop or reverse this devastating disease are urgently needed. Despite advances in understanding its molecular pathology, there are no drugs that can halt its progression. This review takes a tour through phase 2, or higher studies, probing receptor agonist agents interfering with aggregation, inhibitors/modulators of secretases, lipid-lowering agents, and, finally and most extensively, immunotherapy. The fact that phase 3 studies with bapineuzumab and solaneuzumab have recently failed does not invalidate the potential of immunotherapy, as more information is available and new clinical trials are being initiated (AU)</dc:description>
<dc:creator>Villegas, Sandra</dc:creator>
<dc:language>es</dc:language>
<dc:description xml:lang="es">El rápido aumento de las tasas de prevalencia de la enfermedad de Alzheimer hace que se necesiten con urgencia tratamientos dirigidos a prevenir, detener o revertir esta devastadora enfermedad. A pesar de los avances en la comprensión de su patología molecular, todavía no existen fármacos que puedan detener su progresión. Esta revisión hace un recorrido por aquellos estudios en fase 2, o superior, que ensayan agonistas de receptores, sustancias que interfieren en la agregación, inhibidores/moduladores de las secretasas, hipolipidemiantes, y, finalmente y con mayor extensión, las inmunoterapias. El hecho de que recientemente hayan fallado las fases 3 para bapineuzumab y solaneuzumab no invalida el potencial de la inmunoterapia, ya que cada vez disponemos de más información y se están iniciando nuevos ensayos clínicos (AU)</dc:description>
<dc:source>Med. clín (Ed. impr.);145(2): 76-83, jul. 2015. graf, tab</dc:source>
<dc:identifier>ibc-138572</dc:identifier>
<dc:title xml:lang="es">Enfermedad de Alzheimer: nuevas estrategias terapéuticas</dc:title>
<dc:subject>^d29611</dc:subject>
<dc:subject>^d545^s22053</dc:subject>
<dc:subject>^d545^s22054</dc:subject>
<dc:subject>^d29543^s22073</dc:subject>
<dc:subject>^d545^s22033</dc:subject>
<dc:subject>^d52219^s22073</dc:subject>
<dc:subject>^d545^s22057</dc:subject>
<dc:subject>^d21034</dc:subject>
<dc:subject>^d545^s22080</dc:subject>
<dc:subject>^d21030</dc:subject>
<dc:subject>^d29428^s22074</dc:subject>
<dc:subject>^d21044</dc:subject>
<dc:subject>^d29592^s22074</dc:subject>
<dc:subject>^d963^s22073</dc:subject>
<dc:subject>^d1059^s22073</dc:subject>
<dc:subject>^d545^s22027</dc:subject>
<dc:subject>^d28856^s22073</dc:subject>
<dc:subject>^d55004^s22073</dc:subject>
<dc:subject>^d7345^s22074</dc:subject>
<dc:type>article</dc:type>
<dc:date>201507</dc:date>
</metadata>
</record>
</ibecs-document>
